Related Experiment Video
Updated: Aug 3, 2026
08:30
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
Published on: May 16, 2012
Abnormal expression of MDM2 in prostate carcinoma
K R Leite1, M F Franco, M Srougi
1Laboratory of Surgical and Molecular Pathology, Hospital Sirio Libanes, Sao Paulo, Brazil. katiaramos@uol.com.br
Summary
While p53 gene mutations are rare in prostate cancer, detected p53 protein and MDM2 overexpression are common. These findings correlate with aggressive tumor features, suggesting a role in prostate carcinogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- p53 mutations are infrequent in localized prostate cancer.
- MDM2 protein targets p53 for degradation, regulating cell cycle and apoptosis.
- Understanding p53 and MDM2 roles is crucial for prostate cancer prognosis.
Purpose of the Study:
- To investigate the expression of p53 and MDM2 in localized prostate cancer.
- To correlate p53 and MDM2 expression with clinicopathological features and tumor behavior.
- To assess the relationship between p53/MDM2 status and cell proliferation/apoptosis.
Main Methods:
- Immunohistochemistry used to detect p53 and MDM2 protein expression.
- Polymerase chain reaction-single strand conformational polymorphism for p53 mutation analysis.
- Ki-67 and TUNEL assays for cell proliferation and apoptosis assessment.
Main Results:
- No p53 mutations detected; p53 protein detected in 31.4% of cases, linked to higher Gleason scores and advanced stages.
- MDM2 overexpression found in 40.7% of cases, associated with larger tumor volumes.
- Co-expression of p53 and MDM2 correlated with larger tumors and advanced stages; MDM2-positive tumors showed higher proliferation, p53-positive tumors lower apoptosis.
Conclusions:
- p53 protein detection, not mutation, is common in prostate cancer and linked to adverse features.
- MDM2 overexpression plays a role in prostate carcinogenesis, promoting proliferation and tumor growth.
- The MDM2-positive/p53-positive phenotype may indicate aggressive prostate cancer behavior.
Related Concept Videos
01:46Epigenetic Regulation
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
02:23Master Transcription Regulators
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...